Leukemia Research
Volume 27, Issue 9 , Pages 841-851 , September 2003

Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients

  • Caroline Bäumler

      Affiliations

    • Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
    • ,
  • Fei Duan

      Affiliations

    • Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
    • ,
  • Kenan Onel

      Affiliations

    • Rockefeller University, New York, NY 10021, USA
    • Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Beth Rapaport

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Suresh Jhanwar

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Kenneth Offit

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    • ,
  • Keith B. Elkon

      Affiliations

    • Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY 10021, USA
    • Corresponding Author InformationCorresponding author. Present address: Division of Rheumatology, University of Washington, 1959 NE Pacific Street, P.O. Box 356428, Seattle, WA 98195-6428, USA. Tel.: +1-206-543-3414; fax: +1-206-685-9397.

Received 9 September 2002 ,Accepted 26 December 2002.

References 

  1. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879–886
  2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453–456
  3. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–526
  4. Krammer PH. CD95’s deadly mission in the immune system. Nature. 2000;407:789–795
  5. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale–Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 1996;335:1643–1649
  6. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–946
  7. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–1349
  8. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98:194–200
  9. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas–Fas ligand interactions. J. Exp. Med. 1998;187:1825–1838
  10. Peng SL, Robert ME, Hayday AC, Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 1996;184:1149–1154
  11. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90:4266–4270
  12. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998;91:2875–2885
  13. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP. Dysregulation of CD95/CD95 ligand–apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998;92:4771–4777
  14. Bhatia S, Robison LL. Epidemiology of leukemia and lymphoma. Curr. Opin. Hematol. 1999;6:201–204
  15. Lynch HT, Marcus JN, Lynch JF. Genetics of Hodgkin’s and non-Hodgkin’s lymphoma: a review. Cancer Invest. 1992;10:247–256
  16. Siebert R, Louie D, Lacher M, Schluger A, Offit K. Familial Hodgkin’s and non-Hodgkin’s lymphoma: different patterns in first-degree relatives. Leuk. Lymphoma. 1997;27:503–507
  17. Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 1997;272:26953–26958
  18. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245:301–305
  19. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J. Exp. Med. 1985;162:459–471
  20. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al.  Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675–1687
  21. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, et al.  Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 1995;181:1661–1672
  22. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 1999;103:355–363
  23. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373:438–441
  24. Na S, Chuang TH, Cunningham A, Turi TG, Hanke JH, Bokoch GM, et al.  D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis. J. Biol. Chem. 1996;271:11209–11213
  25. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21:4520–4530
  26. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al.  Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 2001;276:46639–46646
  27. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999;274:1541–1548
  28. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al.  Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  29. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, et al.  Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J. Biol. Chem. 2000;275:24357–24366
  30. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein–Barr virus tumorigenesis in Burkitt’s lymphoma. Blood. 1999;94:1727–1737
  31. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 2000;60:5673–5680
  32. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al.  Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363–1366
  33. O’Connell J, Bennett MW, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today. 1999;20:46–52
  34. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13:1854–1858
  35. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, et al.  Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity. Blood. 1998;92:3018–3024
  36. Beltinger C, Kurz E, Bohler T, Schrappe M, Ludwig WD, Debatin KM. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:3943–3951
  37. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 1998;91:3935–3942
  38. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998;161:2833–2840
  39. Ryu BK, Lee MG, Chi SG, Kim YW, Park JH. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 2001;194:15–19
  40. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 1999;190:1033–1038
  41. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 1999;190:1025–1032
  42. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914–6925
  43. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al.  IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215–2223
  44. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683
  45. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, et al.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395–399
  46. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000;6:529–535
  47. Shpilberg O, Modan M, Modan B, Chetrit A, Fuchs Z, Ramot B. Familial aggregation of haematological neoplasms: a controlled study. Br. J. Haematol. 1994;87:75–80
  48. Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp. Hematol. 2001;29:228–233

PII: S0145-2126(03)00018-3

doi: 10.1016/S0145-2126(03)00018-3

Leukemia Research
Volume 27, Issue 9 , Pages 841-851 , September 2003

Article Tools

* Image Usage & Resolution